Treatments that target the transthyretin (TTR) protein, either by stabilizing it or reducing its production, were associated with about a…
Andrea Lobo
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Nerve ultrasound — a scan that uses high-frequency sound waves to create real-time images of the body’s nerves — may…
RNA-targeted therapies — ones that zero in on molecules acting as messengers for genetic information in cells — are safe…
Undergoing a liver transplant and/or receiving disease-modifying treatments significantly improves survival in people with hereditary transthyretin amyloidosis (hATTR), a group…
A specialized MRI technique known as the variable echo time (vTE) sequence may help identify structural changes in nerves linked…
HATTR-PN
NewsMRI parameter may be new FAP biomarker, study suggests
A higher proportion of fat in the tissue that surrounds peripheral nerves, as assessed with a noninvasive MRI scan, may…
HATTR-PN
NewsSudoscan skin test may monitor FAP progression: Study
Sudoscan, a test used to indirectly assess small nerve fiber damage through sweat gland function, may be a marker of…
HATTR-PN
NewsTop 10 FAP stories of 2024
Throughout 2024, Amyloidosis News Today informed our readers about the latest developments in treatment and clinical trials for…
Gly103Arg, a mutation in the TTR gene that has been exclusively reported in Chinese people, is associated with a…
HATTR-PN
NewsCombination therapy may be safe in FAP patients: Study
Combination therapy for hereditary transthyretin amyloidosis (hATTR), a group of conditions including familial amyloid polyneuropathy (FAP), appears to be…